---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-000758"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T03:03:46.137691+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q2 FY2023: organic revenue up 4% to $271.6M; GAAP EPS $0.31 vs $0.49 YoY

## Summary
- Organic revenue grew 4% to $271.6M; reported revenue up 1%.
- GAAP EPS $0.31, down from $0.49; adjusted EPS $0.47, flat YoY (FX headwind $0.02).
- ExoDx Prostate test revenue more than doubled YoY; fourth consecutive record quarter.
- Board declared $0.08/share quarterly dividend, payable Feb 27 to holders of record Feb 13.
- Record GMP protein sales and launch of RNAscope Plus and MauriceFlex instrument.

## SEC filing metadata
- accession: 0001558370-23-000758
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837023000758/0001558370-23-000758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837023000758/tmb-20230202x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-000758
- JSON: https://secwatch.observer/filing/0001558370-23-000758.json
- Plain text: https://secwatch.observer/filing/0001558370-23-000758.txt

## Key facts
- Earnings Releases
  BIO-TECHNE Corp reported financial results for the quarter ended December 31, 2022.
  - Period: the quarter ended December 31, 2022
  - Result: reported results
  source text: A copy of the press release issued by Bio-Techne Corporation on February 2, 2023, describing the results of operations for the quarter ended December 31, 2022, and its financial condition as of December 31, 2022 is attached hereto as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837023000758/0001558370-23-000758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.